Literature DB >> 18924115

Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma.

Sabine Schreck1, Daniela Friebel, Maike Buettner, Luitpold Distel, Gerhard Grabenbauer, Lawrence S Young, Gerald Niedobitek.   

Abstract

Classical Hodgkin Lymphoma (cHL) is morphologically characterized by a small number of tumour cells, Hodgkin and Reed-Sternberg (HRS) cells, surrounded by numerous tumour-infiltrating lymphocytes (TIL). The functional role of these TIL is still controversial. While generally considered to represent an anti-tumour immune response, TIL in cHL might result from the profoundly deregulated immunity of cHL patients. Eighty-seven cases of cHL were available to evaluate the prognostical significance of tumour-infiltrating cytotoxic T lymphocytes (CTL), T helper 1 (Th1) cells, T helper 2 (Th2) cells and regulatory T cells (Treg). We confirm that in cHL the microenvironment is dominated by Th2 cells and Treg and show that large numbers of Th2 cells are associated with significantly improved disease-free survival (p = 0.021) and event-free survival (p = 0.012). Furthermore, a high ratio of Treg over Th2 cells resulted in a significantly shortened disease-free survival (p = 0.025). These observations suggest that Treg may exert inhibitory effects on anti-tumour immune responses mediated through Th2 cells and that Th2 cells may be more important for effective anti-tumour immunity than anticipated. Copyright 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18924115     DOI: 10.1002/hon.878

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  51 in total

1.  Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.

Authors:  Luis F Porrata; Kay Ristow; Joseph P Colgan; Thomas M Habermann; Thomas E Witzig; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Grzegorz S Nowakowski; Carrie Thompson; Svetomir N Markovic
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

Review 2.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

3.  Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.

Authors:  Serena K Perna; Biagio De Angelis; Daria Pagliara; Sayyeda T Hasan; Lan Zhang; Aruna Mahendravada; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Gianpietro Dotti; Barbara Savoldo
Journal:  Clin Cancer Res       Date:  2012-11-13       Impact factor: 12.531

4.  Increased expression of CD4+CD25 +FOXP3+ regulatory T cells correlates with Epstein-Barr virus and has no impact on survival in patients with classical Hodgkin lymphoma in Brazil.

Authors:  Mariane C G Assis; Antonio H F M Campos; Jose S R Oliveira; Fernando A Soares; Joyce M K Silva; Priscilla B Silva; Adriana D Penna; Eni M Souza; Otavio C G Baiocchi
Journal:  Med Oncol       Date:  2012-07-13       Impact factor: 3.064

5.  Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma.

Authors:  Jorge Galvez-Silva; Ossama M Maher; Minjeong Park; Diane Liu; Fiorela Hernandez; Priti Tewari; Yago Nieto
Journal:  Biol Blood Marrow Transplant       Date:  2017-04-20       Impact factor: 5.742

6.  New developments in the pathology of malignant lymphoma: a review of the literature published from August to December 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-03       Impact factor: 0.196

7.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

8.  The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Authors:  Evgeny Klyuchnikov; Ulrike Bacher; Nicolaus Kröger; Ilya Kazantsev; Tatjana Zabelina; Francis Ayuk; Axel Rolf Zander
Journal:  Adv Hematol       Date:  2010-10-26

9.  Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment.

Authors:  S Montes-Moreno
Journal:  Adv Hematol       Date:  2010-10-24

Review 10.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.